Aurobindo Pharma, Jubilant Life Sciences Rated New `Buy' at Goldman Sachs

Aurobindo Pharma Ltd. and Jubilant Life Sciences Ltd. were rated “buy” in new coverage at Goldman Sachs Group Inc., which cited an improving revenue outlook, greater capacity utilization and easing balance sheet concerns.

The brokerage has a share-price estimate of 1,545 rupees for Aurobindo Pharma and a forecast of 408 rupees for Jubilant Life Sciences, according to a report by analysts including Balaji V. Prasad.

To contact the editor responsible for this story: Shiyin Chen at schen37@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.